Understand the basics and why clinical trials matter for new treatments.
A clinical trial is a carefully designed research study that determines whether a medical treatment is safe and effective for humans. Every drug you can buy at a pharmacy, every therapy you might receive, every medical device your doctor uses, all went through clinical trials first. Millions of people have participated in them, and clinical trials have led to treatments that have saved or extended countless lives.
Clinical trials are the mechanism by which medicine gets tested before it becomes available to everyone. They are structured, regulated, and designed with participant safety as a core priority. For many rare diseases, clinical trials represent the only pathway to a treatment, because the patient population is too small for traditional pharmaceutical development without the trial route.
The U.S. Food and Drug Administration (FDA) requires that all new drugs, biologics, and most medical devices undergo clinical trials before approval. The National Institutes of Health (NIH) registry at ClinicalTrials.gov contained more than 500,000 registered studies from over 220 countries as of 2024.
Treatment trials test whether a new drug or therapy works better than existing treatment or placebo for people who already have a condition. These are the most common trials. If you have a disease and you are looking for a trial, you will likely find treatment trials.
Prevention trials test whether something can prevent disease in people who have not been diagnosed. This might include vaccines, supplements, lifestyle changes, or preventive drugs. Examples include the Polyp Prevention Trial and the COVID-19 vaccine trials.
Diagnostic trials test whether a new tool or method can better identify or detect a disease earlier or more accurately. These trials often involve imaging, blood-based biomarkers, or genetic testing approaches.
Screening trials test the best way to detect disease in people who do not yet have symptoms. They are common in cancer, where early detection significantly affects outcomes.
Quality-of-life or supportive care trials test ways to improve comfort or quality of life for people living with a disease or its side effects. They include studies of pain management, fatigue interventions, and rehabilitation strategies.
ClinicalTrials.gov classifies all studies as either interventional or observational. The difference matters when you are deciding what kind of research participation makes sense for you.
Interventional studies (clinical trials) assign participants to receive a specific intervention (a drug, device, behavior, or surgical procedure) according to a research plan. The investigator decides who gets what. Most of what people mean by clinical trial is interventional research.
Observational studies do not assign interventions. Researchers observe what happens to participants in the course of their usual care, with no investigator-directed treatment. Natural history studies (which document how a disease progresses over time without intervention) and patient registries are common observational research designs in rare diseases. Natural history studies are increasingly important for FDA approvals because they create the comparator data that small interventional trials need.
Clinical trial sponsors fall into three main categories. Knowing who is funding a trial helps you understand its goals, scale, and protections.
Pharmaceutical and biotechnology companies sponsor most U.S. clinical trials. Industry-sponsored trials typically test a specific company-owned drug or device with the goal of FDA approval and commercialization. They tend to be well-funded, with strict protocols, established safety reporting infrastructure, and dedicated research staff at each trial site.
The National Institutes of Health (NIH) and other federal agencies (CDC, VA, DoD) sponsor trials focused on questions that may not have clear commercial appeal, including comparative effectiveness studies, prevention research, public health interventions, and rare disease natural history studies. The NIH Clinical Center in Bethesda, Maryland is the largest clinical research hospital in the world and conducts trials at no cost to participants.
Academic medical centers, foundations, and patient organizations sponsor investigator-initiated trials, often using grant funding from NIH, the FDA Orphan Products Grant Program, or disease-specific foundations like the Cystic Fibrosis Foundation Therapeutics Development Network. These trials often address questions of practice (best dosing, drug repurposing) that industry has no incentive to fund.
Trial sites themselves are typically academic medical centers, community hospitals, or specialized research clinics that contract with the sponsor. The principal investigator (PI) at each site is the physician responsible for conducting the trial according to the protocol and protecting participant safety.
Clinical trials in the United States are regulated by multiple overlapping authorities, all of which exist to protect human subjects and ensure data integrity.
The FDA regulates trials of drugs, biologics, and medical devices through the Investigational New Drug (IND) process and the Investigational Device Exemption (IDE) process. FDA reviews protocols before trials begin, audits trial sites during conduct, and reviews the resulting data when the sponsor applies for approval. The FDA can place a clinical hold on a trial at any time for safety reasons.
Institutional Review Boards (IRBs) are independent committees of doctors, scientists, ethicists, and community members that review every U.S. trial before it starts and monitor it as it runs. The IRB approves the informed consent form, evaluates the protocol for ethical concerns, and can require changes or stop the trial.
The Office for Human Research Protections (OHRP), part of HHS, oversees all federally funded research involving human subjects under 45 CFR 46 (the Common Rule). This regulation governs informed consent, vulnerable populations, IRB composition, and reporting requirements for adverse events.
International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines establish global standards for trial design, conduct, monitoring, and reporting. ICH GCP is the de facto worldwide standard, and most regulatory authorities accept data from trials conducted under it.
Modern clinical trial methodology evolved out of mid-20th-century reforms following several public health failures. The 1937 Elixir Sulfanilamide tragedy (in which a poorly tested medication killed more than 100 people, many of them children) prompted the 1938 Federal Food, Drug, and Cosmetic Act, which required premarket safety testing for new drugs.
The 1962 Kefauver-Harris Amendment, passed after the thalidomide birth defect crisis, required drug manufacturers to prove not only that drugs were safe but that they were effective for their intended use. This created the modern requirement for adequate and well-controlled clinical trials before approval.
The 1974 National Research Act and the 1979 Belmont Report established the ethical framework for human subjects research after the Tuskegee Syphilis Study and other documented research abuses. The Belmont principles (respect for persons, beneficence, justice) are the foundation of every modern informed consent process.
The 1983 Orphan Drug Act provided incentives for rare disease drug development and has driven the modernization of clinical trials for small patient populations. Since 1983, FDA has approved more than 700 orphan drugs, many through trials with novel small-population designs.
A rare disease in the United States is one that affects fewer than 200,000 people nationally (per the 1983 Orphan Drug Act). Clinical trials for rare diseases differ from common-condition trials in several important ways that affect both trial design and the participant experience.
Smaller trial populations. Rare disease trials may enroll 20 to 100 patients (rather than the thousands typical of cardiovascular or oncology trials). This means trial sites are concentrated, often at academic referral centers, and travel is more common.
Novel statistical designs. Adaptive designs, basket trials, master protocols, and crossover designs are more common in rare disease trials because traditional large parallel-group designs are impractical with small populations. Many rare disease trials use natural history studies or patient registry data as the comparator instead of placebo.
Higher likelihood of receiving the active drug. Many rare disease trials are open-label (everyone gets the drug), use weighted randomization that favors the active drug arm, or include an open-label extension. The pure placebo-controlled trial is less common in rare diseases than people often assume.
Closer relationships with researchers. Because the participant pool is small, rare disease trial teams often know each participant by name, follow them for years, and integrate trial visits into specialty care. For many rare disease patients, the trial site is also their long-term medical home.
Clinical trials are how we know if something actually works. A therapy that seems promising in the lab might fail in the real world. A drug that works for one person might not work for another. Trials help us understand which treatments are truly effective, for whom, and what the side effects are.
For patients with rare diseases, clinical trials are often the only way to access new treatments years before they might become available through standard prescription channels. Drugs like Casgevy (sickle cell disease, approved 2023), Elevidys (Duchenne muscular dystrophy, approved 2023), and Zolgensma (spinal muscular atrophy, approved 2019) were available to trial participants several years before commercial launch.
Many people participate in trials for reasons that extend beyond themselves, including helping the thousands or millions of others who might eventually benefit from what is learned. For rare disease communities specifically, every trial participant contributes data that builds the foundation for the next generation of therapies.
A clinical trial is a research study in which people volunteer to test a new medical treatment, device, or approach to determine whether it is safe and works as intended. Clinical trials are how every approved drug, vaccine, and medical device gets tested before becoming available to the public. Trials follow a written research plan called a protocol and are reviewed by independent ethics committees before they begin.
The main types of clinical trials are treatment trials (testing new drugs or therapies in people with a condition), prevention trials (testing ways to prevent disease in people without it), diagnostic trials (testing new ways to detect or diagnose disease), screening trials (testing detection methods in asymptomatic people), and quality-of-life or supportive care trials (testing interventions to improve symptoms and well-being).
Clinical trials are paid for by the trial sponsor, which is most often a pharmaceutical or biotechnology company, the National Institutes of Health (NIH), an academic medical center, or a disease-specific foundation. The sponsor pays for the investigational drug, the protocol-required tests and procedures, trial site staffing, and (in many cases) participant travel reimbursement. Routine medical care that participants would have needed anyway is usually billed to insurance, with coverage required by federal law for most plans under the Affordable Care Act.
Clinical trials carry real risk because they test investigational treatments whose full safety profile is still being characterized. They are also tightly regulated, with multiple layers of protection that include FDA review of the protocol, Institutional Review Board (IRB) ethics review, ongoing safety monitoring by the trial sponsor, and (for larger trials) Data Safety Monitoring Boards. Most participants do not experience serious adverse events, but some do, and the risk-benefit balance varies by trial phase and disease severity.
A clinical trial (interventional study) assigns participants to receive a specific treatment (a drug, device, behavior, or surgery) according to a research protocol. An observational study does not assign treatment; researchers observe what happens to participants during their usual care. Natural history studies and patient registries are common observational designs, especially for rare diseases.
The full clinical trial process from preclinical research through FDA approval averages 10 to 15 years. Individual trial phases vary substantially. Phase 1 typically takes several months to 2 years, Phase 2 takes 1 to 3 years, and Phase 3 takes 2 to 4 years. The duration of an individual participant's involvement varies by protocol and can range from a single visit (for some Phase 1 studies) to many years (for long-term follow-up studies of gene therapies, which the FDA requires for 15 years).
Informed consent is the process by which a potential participant learns the key facts of a clinical trial (purpose, procedures, risks, benefits, alternatives, costs, rights) and decides whether to participate. Federal regulations (45 CFR 46) require that informed consent be given freely, that the participant have time to consider and ask questions, and that the consent form be in plain language the participant can understand. Informed consent is an ongoing process; you can withdraw at any time even after signing.
Clinical trials in the United States are regulated by the FDA (which reviews protocols and approves new drugs), Institutional Review Boards (which provide ethics oversight at each site), the Office for Human Research Protections (which enforces 45 CFR 46), and international guidelines like ICH Good Clinical Practice (which set worldwide standards for trial conduct). Trial registration and results reporting are required at ClinicalTrials.gov for most U.S. interventional studies.